Complex treatment of patients with chronic bacterial prostatitis using biologically active peptides
A. I. Neymark, A. V. Davydov, I. V. Kablova · 2022 · Urology Reports. 2022;12(3). DOI:10.17816/uroved109913
Reported findings and study design
The Prostateks add-on group had 91.4% microflora eradication and a reported 89.8% increase in mean volumetric urine flow. Symptom scores improved more than with antibiotic alone, but the abstract does not provide the score changes or control eradication rate.
94 chronic bacterial prostatitis patients aged 21–45; 47 antibiotic-only and 47 antibiotic plus Prostateks suppositories.
Dose, route and schedule
Prostateks rectal suppository 10 mg once daily, added to antibiotic treatment. The indexed publisher abstract does not clearly provide the adjunct-course duration.
Protocol source ↗ · Publisher abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Microflora eradication | 91.4% in the add-on group | Antibiotic + Prostateks; control percentage not supplied |
| Mean volumetric urine flow | +89.8% reported | Add-on arm change; absolute flow values and control change absent |
| NIH-CPSI/IPSS symptoms | Greater improvement reported; numerical score changes not supplied | |
| Treatment groups | 47 + 47 = 94 patients |
Allocation is not described as randomized in the abstract. Percentages are not a placebo-adjusted benefit. “Twice the clinical efficacy” is reported without raw response counts or a defined endpoint; it is not treated as a verified doubling of response probability.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Allocation is not described as randomized in the abstract. Percentages are not a placebo-adjusted benefit. “Twice the clinical efficacy” is reported without raw response counts or a defined endpoint; it is not treated as a verified doubling of response probability.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Publisher abstract checked
Source access and review scope
Original publisher abstract and metadata checked; complete outcome tables not recovered.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Journal publication
Citation and original source
Original source: A. I. Neymark, A. V. Davydov, I. V. Kablova. Complex treatment of patients with chronic bacterial prostatitis using biologically active peptides Urology Reports. 2022;12(3). DOI:10.17816/uroved109913 2022.
Molekul research summary: https://molekul.io/research/prostateks-prostatitis-2022. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry